VIRGINIA BEACH, Va. and MEDFORD, Mass., Feb. 9, 2018 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced an additional leading East Coast-based reproductive services provider has added INVOcell to its list of reproductive treatments.

INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who may otherwise cannot afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.

The New Hope Center for Reproductive Medicine, located in Virginia Beach, Virginia, is now offering INVOcell fertility treatment to their broad palette of fertility services. For many couples dealing with infertility, the cost of in-vitro fertilization (“IVF”) can be a barrier to getting the baby they desire. Others are faced with a religious or cultural dilemma when needing to decide what to do with excess embryos. For couples such as these, a new, more natural method of treatment offered at The New Hope Center – INVOcell^TM could be the answer. The procedure is more cost effective due to the elimination of certain IVF Lab procedures, and typically produces less embryos due to the minimal stimulation/medication regimen used, while still offering a comprehensive treatment option for these couples.

Dr. Robin Poe-Zeigler, founder of The New Hope Center, said, “We are humbled by the thousands of patients who have entrusted us with their care, while assisting them with their fertility journey on the way to parenthood. We are dedicated to providing the highest quality infertility testing and treatment, using cutting edge techniques and technology, including INVOcell, to achieve the best possible outcome for each and every patient. We believe that INVOcell represents a unique option to many couples that could not otherwise undergo fertility treatments in a fiscally responsible manner.”

Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience, commented, “Dr. Robin Poe-Zeigler and The New Hope Center provide great hope and compassion to couples in the mid-Atlantic region that are challenged to achieve the pregnancy they so desire. Throughout the years, Dr. Robin and her team have made pregnancies possible that have brought thousands of babies into the world. We are pleased that The New Hope Center has included our INVOcell treatment as a unique option that can help fulfill the dreams of building families.”

About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/

Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

INVO Bioscience, Inc.

Kathleen Karloff, CEO

978-878-9505 ext. 504

kkarloff@invobio.com